This is the authors' abstract. We don't add key points for this paper.
For the purpose of preparing the ring-expanded analogue of anthracene, 1,2,4,5-tetrakis[(1E,3Z)-4-methylhexa-1,3-dien-5-ynyl]benzene, 8, and 1,2,4,5-tetrakis[(Z)-2(2-ethnylphenyl)ethenyl]benzene, 16, were oxidatively coupled; however, both of them afforded m-bridged derivatives, i.e., 1,3:4,6-bis[(1E,3Z,9Z,11E)-4,9-dimethyldodeca-1,3,9,11-tetraene-5,7-diyne-1,12-diyl]benzene, 3, and 1,3:4,6-bis[(1E,11E)-3,4:9,10-dibenzdodeca-1,11-diene-5,7-diyne-1,12-diyl]benzene, 5. To ascertain the structures of 3 and 5, the related model compounds were also prepared.
No takes yet. Share an insight, caveat, or question.
Kakumi et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: